Why HIV Virions Have Low Numbers of Envelope Spikes: Implications for Vaccine Development

PLoS Pathogens

Volumn 10, Issue 8, 2014, Pages

  Schiller, John ^a   Chackerian, Bryce ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B LYMPHOCYTE RECEPTOR; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; WART VIRUS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CROSS REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; NONHUMAN; VACCINE PRODUCTION; VIRION; VIRUS SPIKE; IMMUNOLOGY; PATHOGENICITY; ULTRASTRUCTURE;

AIDS VACCINES; HIV; HIV INFECTIONS; HUMANS; VIRAL ENVELOPE PROTEINS; VIRION;

EID: 84930373269     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004254     Document Type: Article

References (20)

1. Zhu P, Liu J, Bess J, JrChertova E, Lifson JD, et al. (2006) Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441: 847–852.
2. Powers KA, Poole C, Pettifor AE, Cohen MS, (2008) Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 8: 553–563.
3. Yuste E, Reeves JD, Doms RW, Desrosiers RC, (2004) Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol 78: 6775–6785.
4. Klein JS, Bjorkman PJ, (2010) Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 6: e1000908.
5. Hangartner L, Zinkernagel RM, Hengartner H, (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6: 231–243.
6. Stanley M, (2010) HPV - immune response to infection and vaccination. Infect Agent Cancer 5: 19.
7. Schiller JT, Lowy DR, (2012) Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 10: 681–692.
8. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, et al. (2013) Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 6: 1242–1250.
9. Bachmann MF, Zinkernagel RM, (1996) The influence of virus structure on antibody responses and virus serotype formation. Immun Today 17: 553–558.
10. Chackerian B, Lowy DR, Schiller JT, (2001) Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108: 415–423.
11. Chackerian B, Lenz P, Lowy DR, Schiller JT, (2002) Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169: 6120–6126.
12. Chackerian B, Durfee MR, Schiller JT, (2008) Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J Immunol 180: 5816–5825.
13. Bachmann MF, Whitehead P, (2013) Active immunotherapy for chronic diseases. Vaccine 31: 1777–1784.
14. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, et al. (2003) Predominant autoantibody production by early human B cell precursors. Science 301: 1374–1377.
15. Yarkoni Y, Getahun A, Cambier JC, (2010) Molecular underpinning of B-cell anergy. Immunol Rev 237: 249–263.
16. Mascola JR, Haynes BF, (2013) HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 254: 225–244.
17. West AP, JrScharf L, Scheid JF, Klein F, Bjorkman PJ, et al. (2014) Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156: 633–648.
18. Yang G, Holl TM, Liu Y, Li Y, Lu X, et al. (2013) Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 210: 241–256.
19. Verkoczy L, Diaz M, (2014) Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Curr Opin HIV AIDS 9: 224–234.
20. Wistrom J, Ahlm C, Lundberg S, Settergren B, Tarnvik A, (1999) Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Vaccine 17: 2162–2165.